These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 37535440

  • 1. In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia.
    Zornic S, Petrovic I, Lukovic B.
    Acta Microbiol Immunol Hung; 2023 Sep 21; 70(3):187-192. PubMed ID: 37535440
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
    Öztaş S, Er DK, Dündar D, Keçeli SA.
    Acta Microbiol Immunol Hung; 2024 Jul 02; 71(2):110-120. PubMed ID: 38837219
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates.
    Li D, Yu H, Huang X, Long S, Zhang J.
    Microbiol Spectr; 2023 Dec 12; 11(6):e0280623. PubMed ID: 37982631
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Colistin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from a pediatric hospital from Corrientes, Argentina].
    Pellegrini JL, Aguirre C, Soto SM, Lovera LMR, Lösch LS, Conza JAD, Merino LA.
    Rev Chilena Infectol; 2022 Apr 12; 39(2):109-116. PubMed ID: 35856982
    [Abstract] [Full Text] [Related]

  • 9. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P, Bovo F, Bussini L, Lazzarotto T, Amadesi S, Bartoletti M, Viale P, Ambretti S.
    J Antimicrob Chemother; 2022 May 29; 77(6):1570-1577. PubMed ID: 35373297
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I, Souli M, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Antoniadou A, Study Collaborators.
    Eur J Clin Microbiol Infect Dis; 2019 Jun 29; 38(6):1143-1150. PubMed ID: 30825054
    [Abstract] [Full Text] [Related]

  • 11. Carbapenem antibiotic stress increases blaKPC -2 gene relative copy number and bacterial resistance levels of Klebsiella pneumoniae.
    Chen H, Li N, Wang F, Wang L, Liang W.
    J Clin Lab Anal; 2022 Jul 29; 36(7):e24519. PubMed ID: 35718993
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Resistance Phenotype and Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolates in Shanghai.
    Zhang WX, Chen HY, Chen C, Chen JH, Wan FS, Li LX, Chen M, Zhang J.
    Microb Drug Resist; 2021 Oct 29; 27(10):1312-1318. PubMed ID: 34297609
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ceftazidime/avibactam and eravacycline susceptibility of carbapenem-resistant Klebsiella pneumoniae in two Greek tertiary teaching hospitals.
    Chatzidimitriou M, Chatzivasileiou P, Sakellariou G, Kyriazidi M, Kavvada A, Chatzidimitriou D, Chatzopoulou F, Meletis G, Mavridou M, Rousis D, Katsifa E, Vagdatli E, Mitka S, Theodoros L.
    Acta Microbiol Immunol Hung; 2021 Jun 21; 68(2):65-72. PubMed ID: 33522985
    [Abstract] [Full Text] [Related]

  • 19. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
    Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH.
    Antimicrob Agents Chemother; 2017 Sep 21; 61(9):. PubMed ID: 28630202
    [Abstract] [Full Text] [Related]

  • 20. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS.
    Int J Antimicrob Agents; 2021 Nov 21; 58(5):106439. PubMed ID: 34547421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.